That subjectivity is the biggest cause for concern, there's nothing to stop the FDA at the next review saying "close, but not quite. See you again in 6 months". There must or should be a mechanism for interim reviews or appeal if you're rejecting based on opinions rather than hard data.
"Power corrupts; absolute power corrupts absolutely"
Ann: Presentation- FDA Letter Requires Patient Instruction Update, page-56
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
0.005(1.32%) |
Mkt cap ! $696.8M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.5¢ | 37.5¢ | $4.475M | 11.63M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 37310 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.5¢ | 54981 | 2 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |